Effect of Prophylactic Central Lymph Node Dissection on Locoregional Recurrence in Patients with Papillary Thyroid Microcarcinoma

Table 2

Comparison of clinical and pathological features between PCLND and NLND groups.

	PCLND	NLND	value
	(N = 1484)	(N = 100)
Age	46.92 ± 11.72	48.05 ± 10.89	0.350
Diameter	0.59 ± 0.23	0.56 ± 0.31	0.291
Gender			0.035
Males	326 (22.0%)	13 (13.0%)
Females	1158 (78.0%)	87 (87.0%)
Surgery			<0.001
TT	678 (45.7%)	15 (15.0%)
ST	122 (8.2%)	54 (54.0%)
LT	684 (46.1%)	31 (31.0%)
Multifocality			0.122
No	1100 (74.1%)	81 (82.0%)
Yes	384 (25.9%)	19 (18.0%)
Capsule invasion			<0.001
No	994 (67.0%)	90 (90.0%)
Yes	490 (33.0%)	10 (10.0%)
ETE			0.253
No	1452 (97.8%)	96 (96.0%)
Yes	32 (2.2%)	4 (4.0%)
Occult central lymph node metastases			<0.001
No	1013 (68.3%)	96 (96.0%)
Yes	471 (31.7%)	4 (4.0%)

PCLND, prophylactic central lymph node dissection; NLND, no lymph node dissection; TT, total thyroidectomy; ST, subtotal thyroidectomy; TL, thyroid lobectomy; ETE, extrathyroidal extension.